IN2012DN02793A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02793A
IN2012DN02793A IN2793DEN2012A IN2012DN02793A IN 2012DN02793 A IN2012DN02793 A IN 2012DN02793A IN 2793DEN2012 A IN2793DEN2012 A IN 2793DEN2012A IN 2012DN02793 A IN2012DN02793 A IN 2012DN02793A
Authority
IN
India
Prior art keywords
pyrrolidine
pharmaceuticals
oxo
preparing
processes
Prior art date
Application number
Other languages
English (en)
Inventor
Quesnel Yannick
Turet Laurent
Mercier Joel
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42034570&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN02793(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of IN2012DN02793A publication Critical patent/IN2012DN02793A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IN2793DEN2012 2009-10-23 2010-10-21 IN2012DN02793A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09173912 2009-10-23
PCT/EP2010/006434 WO2011047860A1 (en) 2009-10-23 2010-10-21 2-oxo-1-pyrrolidinyl imidazothiadiazole derivatives

Publications (1)

Publication Number Publication Date
IN2012DN02793A true IN2012DN02793A (zh) 2015-07-24

Family

ID=42034570

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2793DEN2012 IN2012DN02793A (zh) 2009-10-23 2010-10-21

Country Status (29)

Country Link
US (1) US8822508B2 (zh)
EP (1) EP2491045B1 (zh)
JP (1) JP5808020B2 (zh)
KR (1) KR20120102058A (zh)
CN (1) CN102574869A (zh)
AR (1) AR078722A1 (zh)
AU (1) AU2010310100B2 (zh)
BR (1) BR112012009310B8 (zh)
CA (1) CA2778194C (zh)
CL (1) CL2012001031A1 (zh)
CY (1) CY1117288T1 (zh)
DK (1) DK2491045T3 (zh)
EA (1) EA201200616A1 (zh)
ES (1) ES2565515T3 (zh)
HR (1) HRP20160263T1 (zh)
HU (1) HUE028668T2 (zh)
IL (1) IL218696A0 (zh)
IN (1) IN2012DN02793A (zh)
MA (1) MA33679B1 (zh)
ME (1) ME02355B (zh)
MX (1) MX347070B (zh)
PE (1) PE20121562A1 (zh)
PL (1) PL2491045T3 (zh)
RS (1) RS54595B1 (zh)
SI (1) SI2491045T1 (zh)
SM (1) SMT201600076B (zh)
TN (1) TN2012000147A1 (zh)
TW (1) TW201118103A (zh)
WO (1) WO2011047860A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2831830C (en) * 2011-04-18 2017-12-12 Ucb Pharma, S.A. 2-oxo-1-imidazolidinyl imidazothiadiazole derivatives
US9581654B2 (en) 2013-02-12 2017-02-28 Johnson Controls Technology Company Vehicle battery monitoring system
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
WO2015110435A1 (en) 2014-01-21 2015-07-30 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
ES2896331T3 (es) * 2017-07-10 2022-02-24 UCB Biopharma SRL Derivados del 2-oxo-1,3-oxazolidinilimidazotiadiazol
CN110869375B (zh) * 2017-07-10 2022-08-30 Ucb生物制药有限责任公司 2-氧代-1-咪唑烷基咪唑并噻二唑衍生物
CN107827870B (zh) * 2017-10-24 2019-11-08 江苏仁明生物科技有限公司 一种正电子药物[18f]fpmmp及其制备方法与中间体
US11155566B2 (en) * 2017-12-12 2021-10-26 UCB Biopharma SRL 2-OXO-1-pyrrolidinyl imidazothiadiazole derivatives
WO2019215062A1 (en) 2018-05-08 2019-11-14 Ucb Biopharma Sprl 1-imidazothiadiazolo-2h-pyrrol-5-one derivatives
CN113549052B (zh) * 2021-07-09 2022-09-02 首都医科大学脑重大疾病研究中心(北京脑重大疾病研究院) 4-苯基-1-(吡啶-4-基甲基)吡咯烷-2-酮衍生物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8412357D0 (en) 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
GB8412358D0 (en) 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
BRPI0417157A (pt) 2003-12-02 2007-03-06 Ucb Sa composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
US8178533B2 (en) * 2005-06-01 2012-05-15 Ucb Pharma, S.A. 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses

Also Published As

Publication number Publication date
US20120245208A1 (en) 2012-09-27
MX2012003839A (es) 2012-05-08
AU2010310100A1 (en) 2012-05-17
CN102574869A (zh) 2012-07-11
CA2778194C (en) 2016-07-12
DK2491045T3 (en) 2016-03-14
MX347070B (es) 2017-04-11
HUE028668T2 (en) 2016-12-28
CA2778194A1 (en) 2011-04-28
WO2011047860A1 (en) 2011-04-28
EP2491045B1 (en) 2015-12-23
EA201200616A1 (ru) 2012-12-28
HRP20160263T1 (hr) 2016-04-08
PE20121562A1 (es) 2012-11-30
CL2012001031A1 (es) 2012-09-14
SMT201600076B (it) 2016-04-29
AU2010310100B2 (en) 2015-09-10
RS54595B1 (en) 2016-08-31
TW201118103A (en) 2011-06-01
AR078722A1 (es) 2011-11-30
IL218696A0 (en) 2012-05-31
BR112012009310A2 (pt) 2016-06-07
US8822508B2 (en) 2014-09-02
BR112012009310B8 (pt) 2021-05-25
BR112012009310B1 (pt) 2021-01-12
MA33679B1 (fr) 2012-10-01
JP5808020B2 (ja) 2015-11-10
ES2565515T3 (es) 2016-04-05
ME02355B (me) 2016-06-20
SI2491045T1 (sl) 2016-04-29
JP2013508321A (ja) 2013-03-07
EP2491045A1 (en) 2012-08-29
PL2491045T3 (pl) 2016-06-30
KR20120102058A (ko) 2012-09-17
TN2012000147A1 (en) 2013-09-19
CY1117288T1 (el) 2017-04-26

Similar Documents

Publication Publication Date Title
IN2012DN02793A (zh)
MX2011008864A (es) Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales.
MX2010007587A (es) Compuestos que comprenden un grupo ciclobutoxi.
WO2009135646A3 (en) Stable pharmaceutical compositions and their processes for preparation suitable for industrial scale
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
EP2251038A4 (en) SOLID DISPERSION, PHARMACEUTICAL COMPOSITIONS THEREFOR AND METHOD FOR THE PRODUCTION THEREOF
AU2010233994A8 (en) Bispecific anti-ErbB-3/anti-c-Met antibodies
IN2012DN05125A (zh)
GB201106743D0 (en) Novel compounds
IL225626A0 (en) The history of pyrrolidinone, their preparation and remote preparations containing them
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
WO2009115084A3 (de) Pyrrolopyrimidin-derivate und deren verwendungen
WO2010049449A3 (en) Novel salts of sunitinib
MX2012013855A (es) Compuestos de oligobenzamida y su uso.
MX2016000900A (es) Nuevos derivados de indol y de pirrol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
IL207183A (en) Dihydroindolone compounds, a process for their preparation and their pharmaceutical compositions
UA118562C2 (uk) Модулятори рецептора cxcr7
WO2011050054A3 (en) Coumarin compounds as receptor modulators with therapeutic utility
MX2013013436A (es) Derivados de indol sustituidos para el tratamiento de transtornos inmunologicos.
MX349563B (es) Formulacion farmaceutica de fenofibrato nanonizado.
GB0615105D0 (en) Novel compounds
MX2014004210A (es) Derivados de 2-oxo-piperidinilo.
MX2011008126A (es) Compuestos de indol sustituidos como moduladores del receptor 1 de bradiquinina.
TR200909785A1 (tr) Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar.
MX336578B (es) Derivados de n-(imidazolidin-2-ilideno)-heterociclopenta[b] pirididina como moduladores de receptores de alfa 2 adrenergicos.